Dr Timothy Schulz-Utermoehl

Dr. Timothy Schulz-Utermoehl has a diverse work experience in the field of pharmaceuticals and biotechnology.

Dr Timothy co-founded Pandeia Therapeutics in 2020, where they held the roles of Co-founder and Chief Operating Officer. In 2022, the company was acquired, and they continued to support the GPR88 program as it reached the clinic.

In 2022, Dr. Schulz-Utermoehl joined Pheno Therapeutics Ltd as the Head of DMPK. Dr Timothy also served as the Director of DMPK at Mission Therapeutics and Co-Founder of Blacksand Therapeutics during the same year.

Before that, they worked as the Director of DMPK Consulting Limited starting in 2020. Additionally, they co-founded Pencil Biosciences Limited in 2019, where they served as a Non-Executive Director.

In 2018, Dr. Schulz-Utermoehl co-founded Pedanius Therapeutics Limited and held the position of Non-Executive Director until the present day.

Prior to their roles in the start-up industry, they worked at Round Earth as the Chief Operating Officer from 2020 to 2022 and was a Co-founder and Non-Executive Director at Belfry Therapeutics Limited from 2016 to 2021.

Dr Timothy started their career at Sygnature Discovery Limited in 2014, where they held the position of Director and Head of DMPK & Physical Sciences until 2020.

Dr Timothy Schulz-Utermoehl completed their education, starting with the International Baccalaureate at the United World College of South East Asia from 1989 to 1991. Dr Timothy then pursued a B.Sc. in Combined Honours Physiology & Pharmacology at the University of Leeds from 1991 to 1994. Afterwards, they obtained an M.Sc. in Toxicology from the Royal Postgraduate Medical School, University of London, from 1994 to 1995. Finally, they completed their Ph.D. in Biochemistry at Imperial College London from 1996 to 1999.